Munshi Amit
Transaction: 02/21/2026
SELL
Change
-19,089
Price
Not reported
Filing
02/24/2026
Type
SELL
Inhibikase Therapeutics, Inc.
IKT • Medical - Pharmaceuticals
$2.50
▼ -0.02 (-0.79%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$245.78M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 21.7Negative growth trendWeak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$2.50
Change-0.79%
Shares Out98.31M
Market Cap$245.78M
Enterprise Value$75.41M
52W Range1.33 - 2.26
Beta0.97
P/E-4.82
P/B1.47
P/FCF-6.79
EV/EBITDA-1.35
EV/FCF-2.08
Price$2.50
Change-0.79%
Shares Out98.31M
Market Cap$245.78M
Enterprise Value$75.41M
52W Range1.33 - 2.26
Beta0.97
P/E-4.82
P/B1.47
P/FCF-6.79
EV/EBITDA-1.35
EV/FCF-2.08
Earnings Yield-20.73%
FCF Yield-14.73%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio21.70
Quick Ratio21.70
Revenue 5Y-100.00%
Target$6.50
Target Upside160.00%
Target Median$6.50
Target Range5.00 - 8.00
Volume499.99K
Avg Volume844.82K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
41
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
94/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 21.7Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 2 analyst votes · 2026-09-05
50/100
Neutral
Bullish
0
Hold
2
Bearish
0
Price Target
2026-06-30
Low
$5.00
Mean
$5.00
Median
$5.00
High
$5.00
Insider Transactions
Recent executive and insider activity
⚠ 2 high-volume insider sells detected
Cabell Christopher
Transaction: 02/21/2026
SELL
Change
-338,282
Price
Not reported
Filing
02/24/2026
Type
SELL
Aurentz Vincent
Transaction: 02/21/2026
SELL
Change
-255,299
Price
Not reported
Filing
02/24/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Munshi Amit | SELL | -19,089 | Not reported | 02/21/2026 | 02/24/2026 |
| Cabell Christopher | SELL | -338,282 | Not reported | 02/21/2026 | 02/24/2026 |
| Aurentz Vincent | SELL | -255,299 | Not reported | 02/21/2026 | 02/24/2026 |
| McIntyre David | BUY | +986,319 | $2.01 | 01/05/2026 | 01/07/2026 |
| Cabell Christopher | BUY | +900,117 | $2.01 | 01/05/2026 | 01/07/2026 |
| Iwicki Mark T | BUY | +4,982,706 | $2.01 | 01/05/2026 | 01/07/2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | BUY | +2,068,965 | $1.45 | 11/21/2025 | 11/24/2025 |
| Munshi Amit | BUY | +57,265 | Not reported | 02/21/2025 | 08/28/2025 |
| Aurentz Vincent | OTHER | 0 | Not reported | 02/21/2025 | 08/28/2025 |
| Cabell Christopher | OTHER | 0 | Not reported | 02/21/2025 | 08/28/2025 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | OTHER | 0 | Not reported | 06/06/2025 | 07/15/2025 |
| Bellini Roberto | BUY | +108,176 | $1.95 | 06/30/2025 | 07/02/2025 |
| BERMAN DENNIS N | BUY | +108,176 | $1.95 | 06/30/2025 | 07/02/2025 |
| Kush Arvind | BUY | +108,176 | $1.95 | 06/30/2025 | 07/02/2025 |
| Munshi Amit | BUY | +108,176 | $1.95 | 06/30/2025 | 07/02/2025 |
| Canner David | BUY | +108,176 | $1.95 | 06/30/2025 | 07/02/2025 |
| Aurentz Vincent | BUY | +108,176 | $1.95 | 06/30/2025 | 07/02/2025 |
| Aurentz Vincent | BUY | +134,427 | $2.97 | 02/21/2025 | 07/02/2025 |
| Iwicki Mark T | BUY | +602,346 | $2.97 | 02/21/2025 | 07/02/2025 |
| Cabell Christopher | BUY | +1,100,705 | $2.97 | 02/21/2025 | 07/02/2025 |